MLKL-IN-6
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL) . MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects[1].
Product Specifications
UNSPSC
12352005
Target
Mixed Lineage Kinase; Necroptosis
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/mlkl-in-6.html
Purity
98.57
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(OC)/C=C/C(N1C)=NC(N(CC#CC2=CC=CC(O)=C2)C(N3C)=O)=C1C3=O
Molecular Formula
C20H18N4O5
Molecular Weight
394.38
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD21 (Complement Receptor Type 2, Cr2, Complement C3d Receptor, Epstein-Barr Virus Receptor, EBV Receptor, CR2, C3DR, SLEB9) (MaxLight 490) discontinued
Mouse Monoclonal CD40/TNFRSF5 Antibody (OTI8B8) - Azide and BSA Free
Rabbit protein tyrosine kinase (PTK) ELISA Kit